Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients

Table 1 Patient demographics and baseline characteristics

	PegIFNα-2a	ETV	P value
Age (yr), mean	35.41 (95%CI: 32.68-39.03)	35.43 (95%CI: 32.42-38.43)	0.8321
Male	62.86%	68.57%	0.6152
ALT (U/L), mean	34.60 (95%CI: 30.31-38.89)	33.06 (95%CI: 30.15-35.96)	0.7451
HBsAg (IU/mL), mean	6168.8630 (95%CI: 3841.12-8496.60)	5879.4557(95%CI: 3643.06-8115.85)	0.9601
HBeAg (+)	29/44 (65.91%)	(27/44) 61.36%	0.6582

α = 0.05.

¹Non-parametric Wilcoxon test;

²Pearson’s χ² test. ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B envelope antigen; PegIFNα-2a: Pegylated interferon-α-2a; ETV: Entecavir.